Giuseppe Di Grazia

DPYD-Guided Dosing of Metronomic Capecitabine Plus Vinorelbine in Metastatic Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Real-World Retrospective Study.

Journal: JCO precision oncology

Published: August 07, 2026

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 06, 2026

Revisiting Diffuse Gliomas in the Era of Precision Medicine: Molecular Insights and Therapeutic Implications.

Journal: Critical reviews in oncology/hematology

Published: April 10, 2026

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 18, 2025

Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology.

Journal: NPJ breast cancer

Published: July 11, 2025

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.

Journal: Cancers

Published: July 08, 2025

Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer.

Journal: Critical reviews in oncology/hematology

Published: May 05, 2025

Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.

Journal: JNCI cancer spectrum

Published: April 15, 2025

REThinking the role of the RET oncogene in breast cancer.

Journal: Frontiers in oncology

Published: May 03, 2024

Nasopharyngeal Metastasis from Lung Adenocarcinoma: A Case Report and Literature Review.

Journal: Case reports in oncology

Published: January 31, 2024

More Than Meets the Eye: A Case of Breast Cancer Switching from Being Luminal-Androgen-Receptor-Positive to Being Hormone-Receptor-Positive.

Journal: Medicina (Kaunas, Lithuania)

Published: September 27, 2023

Distributed dynamic strain sensing of very long period and long period events on telecom fiber-optic cables at Vulcano, Italy.

Journal: Scientific reports

Published: December 31, 2022

DPYD-Guided Dosing of Metronomic Capecitabine Plus Vinorelbine in Metastatic Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Real-World Retrospective Study.

DPYD-Guided Dosing of Metronomic Capecitabine Plus Vinorelbine in Metastatic Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Real-World Retrospective Study.

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Revisiting Diffuse Gliomas in the Era of Precision Medicine: Molecular Insights and Therapeutic Implications.

Revisiting Diffuse Gliomas in the Era of Precision Medicine: Molecular Insights and Therapeutic Implications.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology.

Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology.

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.

Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer.

Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer.

Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.

Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.

REThinking the role of the RET oncogene in breast cancer.

REThinking the role of the RET oncogene in breast cancer.

Nasopharyngeal Metastasis from Lung Adenocarcinoma: A Case Report and Literature Review.

Nasopharyngeal Metastasis from Lung Adenocarcinoma: A Case Report and Literature Review.

More Than Meets the Eye: A Case of Breast Cancer Switching from Being Luminal-Androgen-Receptor-Positive to Being Hormone-Receptor-Positive.

More Than Meets the Eye: A Case of Breast Cancer Switching from Being Luminal-Androgen-Receptor-Positive to Being Hormone-Receptor-Positive.

Distributed dynamic strain sensing of very long period and long period events on telecom fiber-optic cables at Vulcano, Italy.

Distributed dynamic strain sensing of very long period and long period events on telecom fiber-optic cables at Vulcano, Italy.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.